CA
NZ
UK
AU
IND
US
…
Avitar, Inc., through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine, such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company also provides foam disposable products, including medical-grade hydrophilic polyurethane foam disposables, such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. In addition, it develops specialty wound dressings for the cardiac catheter lab market and the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. The company markets its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations through direct sales force and strategic partners, as well as through a network of distributors. Avitar, Inc. was founded in 1986 and is based in Canton, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Avitar Inc (OTC: AVTI) are limited and the company's core operations are not clearly described in widely available sources. Major long-term growth drivers are therefore not apparent from public filings. Some investors may find exposure to a microcap OTC issuer appealing if management provides clearer strategic direction and financial transparency.
The primary investment risks are limited public disclosure, low liquidity common to OTC-listed microcaps, and material uncertainty about financial condition, governance and execution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2007-09-30 | 2006-09-30 | 2005-09-30 | 2004-09-30 | 2003-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2007-09-30 | 2006-09-30 | 2005-09-30 | 2004-09-30 | 2003-09-30 |
| Income before tax | -2.20M | -3.55M | -2.43M | -2.40M | - |
| Net income | -2.26M | -3.70M | -2.43M | -2.41M | - |
| Selling general administrative | 3.26M | 3.77M | 4.33M | 3.40M | 4.37M |
| Gross profit | 0.84M | 1.37M | 1.33M | 1.34M | 1.33M |
| Ebit | -2.73M | -2.89M | -3.73M | -2.63M | - |
| Operating income | -2.73M | -2.89M | -3.73M | -2.63M | - |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Non recurring | - | 0.14M | 0.10M | - | - |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total revenue | 3.11M | 4.52M | 4.51M | 4.05M | 4.60M |
| Total operating expenses | 5.84M | 7.41M | 8.24M | 6.68M | - |
| Cost of revenue | 2.27M | 3.14M | 3.18M | 2.71M | 3.26M |
| Total other income expense net | 0.53M | -0.66M | 1.29M | 0.23M | - |
| Discontinued operations | -0.06M | -0.15M | -0.15M | -0.01M | - |
| Net income from continuing ops | -2.20M | -3.55M | -2.43M | -2.40M | - |
| Net income applicable to common shares | -2.41M | -3.87M | -4.78M | -4.27M | - |
| Breakdown | 2007-09-30 | 2006-09-30 | 2005-09-30 | 2004-09-30 | 2003-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2007-09-30 | 2006-09-30 | 2005-09-30 | 2004-09-30 | 2003-09-30 |
| Total assets | 1.75M | 2.35M | 2.43M | 2.35M | 3.67M |
| Intangible assets | 0.00M | 0.01M | 0.03M | 0.04M | 0.24M |
| Other current assets | 0.09M | 0.14M | 0.20M | 0.17M | 0.80M |
| Total liab | 8.38M | 7.31M | 3.69M | 2.06M | 4.55M |
| Total stockholder equity | -9.85M | -8.18M | -4.61M | -0.67M | - |
| Deferred long term liab | 0.74M | 0.57M | 0.24M | 0.09M | - |
| Other current liab | 1.12M | 1.81M | 0.67M | 0.19M | 1.83M |
| Common stock | 0.63M | 0.09M | 1.91M | 1.23M | 0.89M |
| Retained earnings | -60.02M | -57.61M | -53.50M | -51.56M | - |
| Other liab | 0.02M | 0.04M | 0.05M | - | - |
| Good will | - | - | 0.14M | 0.24M | 0.24M |
| Other assets | 0.89M | 0.72M | 0.40M | 0.10M | 0.50M |
| Cash | 0.09M | 0.28M | 0.40M | 0.51M | 1.13M |
| Total current liabilities | 4.46M | 4.34M | 2.96M | 2.06M | 3.33M |
| Short term debt | 0.54M | 3.79M | 1.56M | 0.20M | - |
| Short long term debt | 0.54M | 3.79M | 1.56M | 0.20M | - |
| Property plant equipment | 0.22M | 0.32M | 0.30M | 0.29M | 0.24M |
| Total current assets | 0.63M | 1.30M | 1.56M | 1.67M | - |
| Long term investments | - | - | 0.15M | - | - |
| Net tangible assets | -9.85M | -8.19M | -4.77M | -0.95M | - |
| Net receivables | 0.23M | 0.61M | 0.58M | 0.65M | - |
| Long term debt | 3.90M | 2.94M | 0.68M | - | 1.22M |
| Inventory | 0.23M | 0.27M | 0.37M | 0.35M | 0.25M |
| Accounts payable | 0.53M | 0.40M | 0.50M | 0.77M | 1.15M |
| Preferred stock total equity | 3.22M | 3.22M | 3.35M | 0.96M | 0.70M |
| Breakdown | 2007-09-30 | 2006-09-30 | 2005-09-30 | 2004-09-30 | 2003-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2007-09-30 | 2006-09-30 | 2005-09-30 | 2004-09-30 | 2003-09-30 |
| Change to liabilities | 0.74M | 0.27M | -0.44M | -0.90M | 0.09M |
| Total cashflows from investing activities | -0.02M | -0.14M | -0.08M | 0.34M | - |
| Net borrowings | 1.60M | 2.86M | 1.61M | -0.15M | - |
| Total cash from financing activities | 1.60M | 2.70M | 4.11M | 2.63M | 3.09M |
| Change to operating activities | 0.06M | 0.09M | -0.17M | -0.04M | - |
| Net income | -2.26M | -3.70M | -2.43M | -2.41M | - |
| Change in cash | -0.19M | -0.12M | -0.11M | -0.62M | - |
| Total cash from operating activities | -1.77M | -2.67M | -4.14M | -3.60M | - |
| Depreciation | 0.12M | 0.14M | 0.15M | 0.12M | - |
| Other cashflows from investing activities | - | - | - | 0.50M | - |
| Dividends paid | - | -0.02M | -0.02M | -0.02M | - |
| Change to inventory | 0.05M | 0.10M | -0.03M | -0.10M | 0.27M |
| Change to account receivables | 0.33M | -0.02M | 0.06M | -0.12M | 0.45M |
| Sale purchase of stock | - | 0.00M | 0.00M | 0.00M | - |
| Other cashflows from financing activities | - | - | 1.50M | - | - |
| Change to netincome | -1.77M | -0.16M | -1.43M | -0.36M | - |
| Capital expenditures | 0.02M | 0.14M | 0.08M | 0.16M | 0.01M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Avitar, Inc., through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine, such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company also provides foam disposable products, including medical-grade hydrophilic polyurethane foam disposables, such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. In addition, it develops specialty wound dressings for the cardiac catheter lab market and the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. The company markets its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations through direct sales force and strategic partners, as well as through a network of distributors. Avitar, Inc. was founded in 1986 and is based in Canton, Massachusetts.
65 Dan Road, Canton, MA, United States, 02021
781-821-2440
36
| Name | Title | Year Born |
|---|---|---|
| Mr. Cory H. Gelmon | CEO, Pres, Treasurer & Sec. | 1960 |
| Mr. Cory H. Gelmon | CEO, President, Treasurer & Secretary | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...